Family Nurse Practitioner (FNP)
ANCC & AANP Exam Bank –
OB/GYN + Cardiac 2026 Edition
PART I: THE PRIMER
Mastering the intersection of high-acuity cardiovascular and obstetrical-gynecological care is the
definitive hallmark of an elite Family Nurse Practitioner. This document forges professionals by
replacing academic memorization with the clinical intuition necessary to navigate 2026’s
rigorous practice environments.
● AHA 2026 HTN: BP ≥130/80 mmHg is Stage 1; initiate pharmacotherapy if the PREVENT
score is ≥7.5%.
● AHA 2026 PE Categories: Category A is asymptomatic (discharge); Category E is
cardiopulmonary failure (advanced therapies).
● ACOG 2026: Primary hrHPV testing every 5 years (ages 30-65) is preferred;
self-collection is officially validated.
● Breast Cancer USPSTF 2026: Biennial screening mammography strictly mandated
beginning at age 40.
● Maternal RSV 2026: Administer RSVpreF at 32–36 weeks gestation
(September–January).
PART II: THE ELITE TEST BANK
Foundational Syntax & Application
Q1: According to the 2026 AHA/ACC guidelines, which blood pressure reading explicitly
defines the threshold for Stage 1 Hypertension requiring primary lifestyle modifications,
and at what PREVENT score is pharmacotherapy mandated? A) 140/90 mmHg; PREVENT
score ≥10% B) 130/80 mmHg; PREVENT score ≥7.5% C) 120/80 mmHg; PREVENT score ≥5%
D) 135/85 mmHg; PREVENT score ≥10%
● The Answer: B
● Distractor Analysis: Option A relies on outdated JNC-8 criteria. Option C defines
elevated blood pressure, not Stage 1. Option D invents arbitrary thresholds. Relying on
older cardiovascular risk calculators (like the ASCVD risk estimator) rather than the
updated PREVENT tool risks severely undertreating patients.
● The Mentor's Analysis: The 2026 AHA/ACC guidelines firmly establish 130/80 mmHg as
Stage 1 Hypertension. The transition from lifestyle modification to pharmacotherapy in
Stage 1 is dictated by the PREVENT calculator. The revised 7.5% threshold captures a
broader, high-risk population, replacing the previous 10% cutoff.
BP Category Systolic (mmHg) Diastolic (mmHg) 2026 Action Protocol
Normal <120 <80 Annual screening
,BP Category Systolic (mmHg) Diastolic (mmHg) 2026 Action Protocol
Elevated 120-129 <80 Lifestyle modifications
Stage 1 130-139 80-89 Lifestyle; Rx if
PREVENT ≥7.5%
Stage 2 ≥140 ≥90 Dual-agent
pharmacotherapy
Q2: Based on the updated 2026 AHA/ACC Atrial Fibrillation guidelines, a patient
demonstrating structural or electrical findings predisposing them to atrial fibrillation
without a documented arrhythmia is classified under which stage? A) Stage 1 B) Stage 2
C) Stage 3A D) Stage 4
● The Answer: B
● Distractor Analysis: Option A (Stage 1) denotes patients merely at risk due to lifestyle or
clinical factors. Option C (Stage 3A) indicates active paroxysmal AFib. Option D (Stage 4)
is permanent AFib where rhythm control has been abandoned.
● The Mentor's Analysis: The 2026 AFib staging reflects a progressive disease continuum
rather than episodic management. Stage 2 (Pre-AFib) recognizes that atrial structural
remodeling precedes the clinical arrhythmia, mandating aggressive upstream risk factor
modification and lifestyle pillars to halt progression before irreversible electrical changes
occur.
Q3: The 2026 AHA/ACC Acute Pulmonary Embolism guidelines introduce a 5-category
severity system. Which category describes an asymptomatic patient who can be safely
discharged home from the emergency department? A) Category A B) Category B C)
Category C D) Category D
● The Answer: A
● Distractor Analysis: Category B patients are symptomatic but possess a low clinical
severity score. Category C patients present with right ventricular dysfunction or elevated
biomarkers and require admission. Category D represents incipient cardiopulmonary
failure.
● The Mentor's Analysis: Category A specifically defines subclinical, asymptomatic PE.
The clinical intuition here centers on disposition confidence: Category A eliminates
unnecessary admissions, allowing immediate outpatient management. The A-E
classification system completely replaces the older "massive/submassive" terminology.
Q4: Under the 2026 USPSTF guidelines, what is the absolute mandate for initiating
screening mammography in average-risk females? A) Annual screening beginning at age
45. B) Biennial screening beginning at age 50. C) Biennial screening beginning at age 40. D)
Annual screening beginning at age 40.
● The Answer: C
● Distractor Analysis: Option B reflects obsolete USPSTF guidance that delayed
screening. Options A and D reflect variations of American Cancer Society (ACS)
guidelines, but the strictly mandated 2026 USPSTF update requires biennial screening at
age 40.
● The Mentor's Analysis: The 2026 USPSTF update lowered the initiation age by a full
decade from 50 to 40 years. This aligns major clinical institutions and removes ambiguity
regarding the baseline surveillance of early-onset malignancies. Screening continues
biennially through age 74.
Q5: For average-risk women aged 30 to 65, the 2026 HRSA/WPSI guidelines prioritize
which methodology as the preferred cervical cancer screening protocol? A) Cervical
, cytology alone every 3 years. B) Primary hrHPV testing every 5 years, including patient
self-collection options. C) Co-testing every 3 years. D) Annual cervical cytology.
● The Answer: B
● Distractor Analysis: Option A is the contingency if hrHPV is unavailable. Option C uses
an incorrect interval for co-testing (which should be 5 years). Option D represents
obsolete over-screening that risks unnecessary cervical excisions.
● The Mentor's Analysis: Primary hrHPV testing every 5 years is the 2026 gold standard.
The addition of FDA-validated patient self-collection for hrHPV directly combats structural
drivers of health by increasing accessibility for marginalized and under-screened
populations.
Q6: According to the CDC and ACOG 2026 maternal immunization protocols, what is the
exact administrative window and dosing strategy for the RSVpreF (Abrysvo) vaccine? A)
28-32 weeks gestation, administered year-round. B) 32-36 weeks gestation, September through
January, single lifetime dose. C) 32-36 weeks gestation, repeated in every subsequent
pregnancy. D) 36-40 weeks gestation, October through March.
● The Answer: B
● Distractor Analysis: Option A administers the vaccine too early. Option C violates the
2026 directive against repeat dosing in subsequent pregnancies. Option D misses the
peak placental transfer window necessary for neonatal passive immunity.
● The Mentor's Analysis: The 32-36 week window ensures optimal maternal antibody
generation and placental transfer before delivery. Limiting administration strictly to the
September-January seasonal window prevents off-cycle waning immunity. CDC currently
prohibits repeat administration in subsequent pregnancies.
Q7: The 2026 Monash University International PCOS Guidelines endorse a revised
Rotterdam criteria. For adult patients, which novel diagnostic marker is now officially
validated as a substitute for ultrasound morphology? A) Elevated luteinizing hormone (LH)
to FSH ratio. B) Elevated Anti-Mullerian Hormone (AMH) levels. C) Fasting insulin > 20 mIU/L.
D) Endometrial biopsy showing hyperplasia.
● The Answer: B
● Distractor Analysis: Option A is an outdated biochemical marker no longer required.
Option C is a consequence of PCOS, not a diagnostic criterion. Option D is a complication
of chronic anovulation, not a primary diagnostic tool.
● The Mentor's Analysis: Elevated AMH directly reflects an increased number of
pre-antral follicles. It definitively replaces the need for transvaginal ultrasound in adult
patients, streamlining diagnosis and reducing invasive testing burdens. Note that AMH
cannot be used in adolescents.
Q8: The 2026 CDC STI Treatment Guidelines designate which pharmacological regimen
as the definitive first-line therapy for an uncomplicated urogenital Chlamydia trachomatis
infection in a non-pregnant adult? A) Azithromycin 1 g orally in a single dose. B) Doxycycline
100 mg orally twice daily for 7 days. C) Ceftriaxone 500 mg IM in a single dose. D) Levofloxacin
500 mg orally once daily for 7 days.
● The Answer: B
● Distractor Analysis: Option A is no longer first-line for non-pregnant adults due to clinical
failure rates in rectal reservoirs. Option C treats Gonorrhea. Option D is a second-line
alternative.
● The Mentor's Analysis: Doxycycline outperforms azithromycin in eradicating concurrent
rectal reservoirs of chlamydia, which commonly coexist with urogenital infections
regardless of reported sexual practices. Azithromycin is reserved strictly for pregnant
ANCC & AANP Exam Bank –
OB/GYN + Cardiac 2026 Edition
PART I: THE PRIMER
Mastering the intersection of high-acuity cardiovascular and obstetrical-gynecological care is the
definitive hallmark of an elite Family Nurse Practitioner. This document forges professionals by
replacing academic memorization with the clinical intuition necessary to navigate 2026’s
rigorous practice environments.
● AHA 2026 HTN: BP ≥130/80 mmHg is Stage 1; initiate pharmacotherapy if the PREVENT
score is ≥7.5%.
● AHA 2026 PE Categories: Category A is asymptomatic (discharge); Category E is
cardiopulmonary failure (advanced therapies).
● ACOG 2026: Primary hrHPV testing every 5 years (ages 30-65) is preferred;
self-collection is officially validated.
● Breast Cancer USPSTF 2026: Biennial screening mammography strictly mandated
beginning at age 40.
● Maternal RSV 2026: Administer RSVpreF at 32–36 weeks gestation
(September–January).
PART II: THE ELITE TEST BANK
Foundational Syntax & Application
Q1: According to the 2026 AHA/ACC guidelines, which blood pressure reading explicitly
defines the threshold for Stage 1 Hypertension requiring primary lifestyle modifications,
and at what PREVENT score is pharmacotherapy mandated? A) 140/90 mmHg; PREVENT
score ≥10% B) 130/80 mmHg; PREVENT score ≥7.5% C) 120/80 mmHg; PREVENT score ≥5%
D) 135/85 mmHg; PREVENT score ≥10%
● The Answer: B
● Distractor Analysis: Option A relies on outdated JNC-8 criteria. Option C defines
elevated blood pressure, not Stage 1. Option D invents arbitrary thresholds. Relying on
older cardiovascular risk calculators (like the ASCVD risk estimator) rather than the
updated PREVENT tool risks severely undertreating patients.
● The Mentor's Analysis: The 2026 AHA/ACC guidelines firmly establish 130/80 mmHg as
Stage 1 Hypertension. The transition from lifestyle modification to pharmacotherapy in
Stage 1 is dictated by the PREVENT calculator. The revised 7.5% threshold captures a
broader, high-risk population, replacing the previous 10% cutoff.
BP Category Systolic (mmHg) Diastolic (mmHg) 2026 Action Protocol
Normal <120 <80 Annual screening
,BP Category Systolic (mmHg) Diastolic (mmHg) 2026 Action Protocol
Elevated 120-129 <80 Lifestyle modifications
Stage 1 130-139 80-89 Lifestyle; Rx if
PREVENT ≥7.5%
Stage 2 ≥140 ≥90 Dual-agent
pharmacotherapy
Q2: Based on the updated 2026 AHA/ACC Atrial Fibrillation guidelines, a patient
demonstrating structural or electrical findings predisposing them to atrial fibrillation
without a documented arrhythmia is classified under which stage? A) Stage 1 B) Stage 2
C) Stage 3A D) Stage 4
● The Answer: B
● Distractor Analysis: Option A (Stage 1) denotes patients merely at risk due to lifestyle or
clinical factors. Option C (Stage 3A) indicates active paroxysmal AFib. Option D (Stage 4)
is permanent AFib where rhythm control has been abandoned.
● The Mentor's Analysis: The 2026 AFib staging reflects a progressive disease continuum
rather than episodic management. Stage 2 (Pre-AFib) recognizes that atrial structural
remodeling precedes the clinical arrhythmia, mandating aggressive upstream risk factor
modification and lifestyle pillars to halt progression before irreversible electrical changes
occur.
Q3: The 2026 AHA/ACC Acute Pulmonary Embolism guidelines introduce a 5-category
severity system. Which category describes an asymptomatic patient who can be safely
discharged home from the emergency department? A) Category A B) Category B C)
Category C D) Category D
● The Answer: A
● Distractor Analysis: Category B patients are symptomatic but possess a low clinical
severity score. Category C patients present with right ventricular dysfunction or elevated
biomarkers and require admission. Category D represents incipient cardiopulmonary
failure.
● The Mentor's Analysis: Category A specifically defines subclinical, asymptomatic PE.
The clinical intuition here centers on disposition confidence: Category A eliminates
unnecessary admissions, allowing immediate outpatient management. The A-E
classification system completely replaces the older "massive/submassive" terminology.
Q4: Under the 2026 USPSTF guidelines, what is the absolute mandate for initiating
screening mammography in average-risk females? A) Annual screening beginning at age
45. B) Biennial screening beginning at age 50. C) Biennial screening beginning at age 40. D)
Annual screening beginning at age 40.
● The Answer: C
● Distractor Analysis: Option B reflects obsolete USPSTF guidance that delayed
screening. Options A and D reflect variations of American Cancer Society (ACS)
guidelines, but the strictly mandated 2026 USPSTF update requires biennial screening at
age 40.
● The Mentor's Analysis: The 2026 USPSTF update lowered the initiation age by a full
decade from 50 to 40 years. This aligns major clinical institutions and removes ambiguity
regarding the baseline surveillance of early-onset malignancies. Screening continues
biennially through age 74.
Q5: For average-risk women aged 30 to 65, the 2026 HRSA/WPSI guidelines prioritize
which methodology as the preferred cervical cancer screening protocol? A) Cervical
, cytology alone every 3 years. B) Primary hrHPV testing every 5 years, including patient
self-collection options. C) Co-testing every 3 years. D) Annual cervical cytology.
● The Answer: B
● Distractor Analysis: Option A is the contingency if hrHPV is unavailable. Option C uses
an incorrect interval for co-testing (which should be 5 years). Option D represents
obsolete over-screening that risks unnecessary cervical excisions.
● The Mentor's Analysis: Primary hrHPV testing every 5 years is the 2026 gold standard.
The addition of FDA-validated patient self-collection for hrHPV directly combats structural
drivers of health by increasing accessibility for marginalized and under-screened
populations.
Q6: According to the CDC and ACOG 2026 maternal immunization protocols, what is the
exact administrative window and dosing strategy for the RSVpreF (Abrysvo) vaccine? A)
28-32 weeks gestation, administered year-round. B) 32-36 weeks gestation, September through
January, single lifetime dose. C) 32-36 weeks gestation, repeated in every subsequent
pregnancy. D) 36-40 weeks gestation, October through March.
● The Answer: B
● Distractor Analysis: Option A administers the vaccine too early. Option C violates the
2026 directive against repeat dosing in subsequent pregnancies. Option D misses the
peak placental transfer window necessary for neonatal passive immunity.
● The Mentor's Analysis: The 32-36 week window ensures optimal maternal antibody
generation and placental transfer before delivery. Limiting administration strictly to the
September-January seasonal window prevents off-cycle waning immunity. CDC currently
prohibits repeat administration in subsequent pregnancies.
Q7: The 2026 Monash University International PCOS Guidelines endorse a revised
Rotterdam criteria. For adult patients, which novel diagnostic marker is now officially
validated as a substitute for ultrasound morphology? A) Elevated luteinizing hormone (LH)
to FSH ratio. B) Elevated Anti-Mullerian Hormone (AMH) levels. C) Fasting insulin > 20 mIU/L.
D) Endometrial biopsy showing hyperplasia.
● The Answer: B
● Distractor Analysis: Option A is an outdated biochemical marker no longer required.
Option C is a consequence of PCOS, not a diagnostic criterion. Option D is a complication
of chronic anovulation, not a primary diagnostic tool.
● The Mentor's Analysis: Elevated AMH directly reflects an increased number of
pre-antral follicles. It definitively replaces the need for transvaginal ultrasound in adult
patients, streamlining diagnosis and reducing invasive testing burdens. Note that AMH
cannot be used in adolescents.
Q8: The 2026 CDC STI Treatment Guidelines designate which pharmacological regimen
as the definitive first-line therapy for an uncomplicated urogenital Chlamydia trachomatis
infection in a non-pregnant adult? A) Azithromycin 1 g orally in a single dose. B) Doxycycline
100 mg orally twice daily for 7 days. C) Ceftriaxone 500 mg IM in a single dose. D) Levofloxacin
500 mg orally once daily for 7 days.
● The Answer: B
● Distractor Analysis: Option A is no longer first-line for non-pregnant adults due to clinical
failure rates in rectal reservoirs. Option C treats Gonorrhea. Option D is a second-line
alternative.
● The Mentor's Analysis: Doxycycline outperforms azithromycin in eradicating concurrent
rectal reservoirs of chlamydia, which commonly coexist with urogenital infections
regardless of reported sexual practices. Azithromycin is reserved strictly for pregnant
